^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cabotamig (ARB202)

    i
    Associations
    News

    Trials

    Company:
    Arbele
    Drug class:
    CD3 agonist, CDH17 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (NCT05411133)
    Phase 1
    Arbele Pty Ltd
    Recruiting
    Last update posted :
    01/23/2024
    Initiation :
    05/30/2022
    Primary completion :
    11/01/2024
    Completion :
    08/01/2025
    CDH17
    |
    CDH1 expression
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)